BackgroundAbnormally　regulated　long　non-coding　RNAs　(lncRNAs)　functions　in　cancer　emphasize　their　potential　to　serve　as　potential　targets　for　cancer　therapeutic　intervention.　LncRNA　ASBEL　has　been　identified　as　oncogene　and　an　anti-sense　transcript　of　tumor-suppressor　gene　of　BTG3　in　triple-negative　breast　cancer　(TNBC).ResultsHerein,　multicomponent　self-assembled　polyelectrolyte　nanocomplexes　(CANPs)　based　on　the　polyelectrolytes　of　bioactive　hyaluronic　acid　(HA)　and　chitosan　hydrochloride　(CS)　were　designed　and　prepared　for　the　collaborative　modulation　of　oncogenic　lncRNA　ASBEL　with　antago3,　an　oligonucleotide　antagonist　targeting　lncRNA　ASBEL　and　hydrophobic　curcumin　(Cur)　co-delivery　for　synergetic　TNBC　therapy.　Antago3　and　Cur　co-incorporated　CANPs　were　achieved　via　a　one-step　assembling　strategy　with　the　cooperation　of　noncovalent　electrostatic　interactions,　hydrogen-bonding,　and　hydrophobic　interactions.　Moreover,　the　multicomponent　assembled　CANPs　were　ulteriorly　decorated　with　a　near-infrared　fluorescence　(NIRF)　Cy-5.5　dye　(FCANPs)　for　synchronous　NIRF　imaging　and　therapy　monitoring　performance.　Resultantly,　MDA-MB-231　cells　proliferation,　migration,　and　invasion　were　efficiently　inhibited,　and　the　highest　apoptosis　ratio　was　induced　by　FCANPs　with　coordination　patterns.　At　the　molecular　level,　effective　regulation　of　lncRNA　ASBEL/BTG3　and　synchronous　regulation　of　Bcl-2　and　c-Met　pathways　could　be　observed.ConclusionAs　expected,　systemic　administration　of　FCANPs　resulted　in　targeted　and　preferential　accumulation　of　near-infrared　fluorescence　signal　and　Cur　in　the　tumor　tissue.　More　attractively,　systemic　FCANPs-mediated　collaborative　modulating　lncRNA　ASBEL/BTG3　and　Cur　co-delivery　significantly　suppressed　the　MDA-MB-231　xenograft　tumor　growth,　inhibited　metastasis　and　extended　survival　rate　with　negligible　systemic　toxicity.　Our　present　study　represented　an　effective　approach　to　developing　a　promising　theranostic　platform　for　combating　TNBC　in　a　combined　therapy　pattern.